Valuation dashboard for Polyrizon Ltd. (PLRZ) with P/E N/A, P/B N/A, EV/EBITDA N/A and dividend yield N/A. DCF, Graham Number and Earnings Power Value models plus sector comparison against other Healthcare companies.
Polyrizon Ltd. is an Israeli biotechnology firm specializing in the creation of medical device hydrogels, delivered as nasal sprays. These innovative sprays are designed to form a protective barrier within the nasal cavity, preventing viruses and allergens from attaching to the nasal epithelial tissue.
Analysis Summary
Balance sheet quality for PLRZ: current ratio of 29.0. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Models
| DCF Fair Value | $0.81 |
| vs Current Price | -92.4% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| PLRZ | Polyrizon Ltd. | $12M | |||
| 0QZU.L | Vertex Pharmaceuticals Incorporated | $131.8B | |||
| VRTX | Vertex Pharmaceuticals Incorporated | $130.6B | 29.76 | 6.46 | 23.3% |
| 0R2M.L | Regeneron Pharmaceuticals, Inc. | $84.0B | |||
| REGN | Regeneron Pharmaceuticals, Inc. | $79.8B | 18.79 | 2.57 | 13.8% |
| ARGX | argenx SE | $61.2B | 36.30 | 7.40 | 21.7% |
| MRNA | Moderna, Inc. | $57.8B | 1.34 | -39.2% | |
| RVMD | Revolution Medicines, Inc. | $41.7B | 15.96 | -96.4% |
Price
| Price | $10.65 |
| Market Cap | $12M |
| Exchange | NASDAQ |
| Country | IL |
Related companies: AIM · CYCN · KTTA · NBY · PMCB · QNRX · RADX
Explore sector: Healthcare · Biotechnology
More sections of PLRZ: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks